Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists
Open accessThe DOI matches its Crossref record.
Abstract
Filoviruses, consisting of Ebola virus (EBOV) and Marburg virus (MARV), are among the most lethal infectious threats to mankind. Infections by these viruses can cause severe hemorrhagic fevers in humans and nonhuman primates with high mortality rates. Since there is currently no vaccine or antiviral therapy approved for humans, there is an urgent need to develop prophylactic and therapeutic options for use during filoviral outbreaks and bioterrorist attacks. One of the ideal targets against filoviral infection and diseases is at the entry step, which is mediated by the filoviral glycoprotein (GP). In this report, we screened a chemical library of small molecules and identified numerous inhibitors, which are known G protein-coupled receptor (GPCR) antagonists targeting different GPCRs, including histamine receptors, 5-HT (serotonin) receptors, muscarinic acetylcholine receptor, and adrenergic receptor. These inhibitors can effectively block replication of both infectious EBOV and MARV, indicating a broad antiviral activity of the GPCR antagonists. The time-of-addition experiment and microscopic studies suggest that GPCR antagonists block filoviral entry at a step following the initial attachment but prior to viral/cell membrane fusion. These results strongly suggest that GPCRs play a critical role in filoviral entry and GPCR antagonists can be developed as an effective anti-EBOV/MARV therapy. IMPORTANCE Infection of Ebola virus and Marburg virus can cause severe illness in humans with a high mortality rate, and currently there is no FDA-approved vaccine or therapeutic treatment available. The 2013-2015 epidemic in West Africa underscores a lack of our understanding in the infection and pathogenesis of these viruses and the urgency of drug discovery and development. In this study, we have identified numerous inhibitors that are known G protein-coupled receptor (GPCR) antagonists targeting different GPCRs. These inhibitors can effectively block replication of both infectious EBOV and MARV, indicating a broad antiviral activity of the GPCR antagonists. Our results strongly suggest that GPCRs play a critical role in filoviral entry and GPCR antagonists can be developed as an effective anti-EBOV/MARV therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Virus–Receptor Interactions: The Key to Cellular Invasion
Maginnis, M. S. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.06.024 · Cited by 413
Choudhary, S., Malik, Y. S., & Tomar, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01664 · Cited by 231
“GR hydrochloride is an antagonist of 5-HT1B/1D serotonin receptor, and also plays a role in inhibiting entry of Ebola virus entry into host cell (45).”
BackgroundThe natural product eugenol is an inhibitor of the ebola virus in vitro
Lane, T., Anantpadma, M., Freundlich, J. S., Davey, R. A., Madrid, P. B., & Ekins, S. (2019) · Pharmaceutical Research · doi:10.1007/s11095-019-2629-0 · Cited by 88
Machine learning models identify molecules active against the Ebola virus in vitro
Ekins, S., Freundlich, J. S., Clark, A. M., Anantpadma, M., Davey, R. A., & Madrid, P. (2015) · F1000Research · doi:10.12688/f1000research.7217.1 · Cited by 84
Ebola Virus Bayesian Machine Learning Models Enable New in Vitro Leads
Anantpadma, M., Lane, T., Zorn, K. M., Lingerfelt, M. A., Clark, A. M., Freundlich, J. S., Davey, R. A., Madrid, P. B., & Ekins, S. (2019) · ACS Omega · doi:10.1021/acsomega.8b02948 · Cited by 54
Metadata
- Authors
- Cheng, H., Lear-Rooney, C. M., Johansen, L., Varhegyi, E., Chen, Z. W., Olinger, G. G., & Rong, L.
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2015-10
- Volume
- 89
- Issue
- 19
- Pages
- 9932-9938
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- OpenAlex
- W2138289533
- Cited by
- 117
- References
- 0
- FWCI
- 8.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists. https://app.cochat.ai/papers/10.1128/jvi.01337-15
- The paper
- Cheng, H., Lear-Rooney, C. M., Johansen, L., Varhegyi, E., Chen, Z. W., Olinger, G. G., & Rong, L. (2015). Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists. Journal of Virology. https://doi.org/10.1128/jvi.01337-15
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.